Amgen Epogen Profit Margins Could Rise 1% After Columbia Patent Expires
Amgen could see its profit margins on Epogen increase by 1% in August if Columbia University fails to obtain a five-year extension on a biotechnology process patent.
Amgen could see its profit margins on Epogen increase by 1% in August if Columbia University fails to obtain a five-year extension on a biotechnology process patent.